Allstocks.com's Bulletin Board Post New Topic  New Poll  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Hot Stocks Free for All ! » NEOP (0.28) big news before bell

 - UBBFriend: Email this page to someone!    
Author Topic: NEOP (0.28) big news before bell
indef
Member


Icon 1 posted      Profile for indef     Send New Private Message       Edit/Delete Post   Reply With Quote 
Neoprobe and ESTECH Announce Distribution Agreement; ESTECH to Distribute Quantix Blood Flow Devices in U.S.
Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that it has entered into a national distribution agreement with ESTECH, Inc. (privately held) of Danville, CA, for distribution in the U.S. of the Quantix/OR blood flow measurement system. The Quantix/OR is designed to provide surgeons with quantitative hemodynamic information in coronary artery bypass graft (CABG) and carotid endarterectomy procedures.

"We believe that this agreement is an important step in our continuing effort to provide physicians with innovative new technologies for improving cardiac surgery outcomes," said Ray Bertolero, ESTECH Vice President and co-founder. "The Quantix/OR system complements our current offerings for cardiovascular surgery and provides us with a unique opportunity to expand our product offering for cardiovascular surgery in the U.S. market."

"The ESTECH agreement provides us with a proven national marketing organization and validates our belief in the blood flow measurement market," said David Bupp, President of Neoprobe. "By joining a leader in servicing the CABG marketplace, the Quantix/OR system will be better positioned to achieve broader market penetration. The strength of ESTECH's product offering will allow us to establish a strong presence in the key market for our blood flow products."

About ESTECH

ESTECH headquartered in San Ramon, CA offers tools for least invasive techniques and traditional approaches to the procedures that cardiac surgeons do every day - coronary artery bypass, valve surgery, atrial ablation and surgical treatment of congestive heart failure.

About Neoprobe

Neoprobe develops and provides innovative surgical and diagnostic products that enhance patient care by meeting the critical decision making needs of healthcare professionals. Neoprobe currently markets the neo2000(R) line of gamma detection systems that are widely used by cancer surgeons for intraoperative lymphatic mapping and the Quantix(R) line of blood flow measurement products that are designed to be used by cardiovascular surgeons, neurosurgeons and critical care physicians. In addition, Neoprobe holds significant interests in the development of related biomedical systems and agents including Lymphoseek(TM) and RIGScan(R) CR. Lymphoseek is an investigational drug being developed as a lymphatic tracing agent. The RIGS(R) system is an investigational technology that combines the Company's gamma detection device technology with a proprietary disease-specific radiolabeled cancer targeting agent that is injected into a cancer patient prior to their surgery, and a patented surgical method to get real-time information to locate tumor deposits that may not be detectable by conventional methods. www.neoprobe.com


Neoprobe Corporation
Brent Larson, 614-793-7500
or
The Trout Group
Tim Ryan, 212-477-9007


Source: Business Wire (June 7, 2006 - 3:33 PM EDT)

News by QuoteMedia
www.quotemedia.com

Posts: 420 | From: Canada | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator
trade04
Member


Rate Member
Icon 1 posted      Profile for trade04     Send New Private Message       Edit/Delete Post   Reply With Quote 
hmm has some insider buying too. how was eod action?
Posts: 3086 | From: miami | Registered: Nov 2005  |  IP: Logged | Report this post to a Moderator
indef
Member


Icon 1 posted      Profile for indef     Send New Private Message       Edit/Delete Post   Reply With Quote 
almost all volume after PR

Price Size Exch Time
0.28 2500 OBB 15:58:30
0.28 2500 OBB 15:58:26
0.28 5000 OBB 15:56:02
0.28 3600 OBB 15:55:44
0.285 10000 OBB 15:55:44
0.28 2000 OBB 15:48:58
0.28 5000 OBB 15:46:15
0.28 25000 OBB 15:42:03
0.275 10000 OBB 15:41:48
0.28 15000 OBB 15:41:48
0.28 25000 OBB 15:41:48
0.275 5000 OBB 15:41:06
0.28 1250 OBB 15:40:22
0.275 5000 OBB 15:39:11
0.28 9600 OBB 15:35:15
0.28 3836 OBB 15:35:15
0.28 5000 OBB 15:35:14
0.28 10000 OBB 15:35:14
0.28 5000 OBB 15:35:11
0.28 10000 OBB 15:35:10
0.28 10000 OBB 15:35:05
0.28 5000 OBB 15:34:56
0.28 1000 OBB 15:34:49
0.28 4000 OBB 15:34:43
0.275 15000 OBB 15:34:30
0.28 10000 OBB 15:34:25
0.275 5000 OBB 15:34:16
0.274 15000 OBB 15:34:16
0.27 21800 OBB 15:34:01
0.27 10000 OBB 15:33:59

Posts: 420 | From: Canada | Registered: Feb 2006  |  IP: Logged | Report this post to a Moderator
Repoman75
Member


Rate Member
Icon 1 posted      Profile for Repoman75         Edit/Delete Post   Reply With Quote 
Radaring.. what's the structure?

--------------------
Stick with Repo's plan in '07 - FRPT/DKAM!

Posts: 6379 | From: PA | Registered: Dec 2004  |  IP: Logged | Report this post to a Moderator
metal1
Member


Rate Member
Icon 1 posted      Profile for metal1     Send New Private Message       Edit/Delete Post   Reply With Quote 
nice move today...

DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB:NEOP - News), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, announced today it has signed a term sheet with Cardinal Health for the marketing and distribution of Lymphoseek® on an exclusive basis in the United States through Cardinal Health's network of over 150 nuclear pharmacies as well as their wholesale distribution operations to in-hospital nuclear pharmacies.
ADVERTISEMENT


Lymphoseek (Technetium Tc99m DTPA-mannosyl-dextran) is a proprietary radioactive lymphatic mapping targeting agent being developed by Neoprobe for use with handheld gamma detection devices, such as Neoprobe's neo2000® system, in a surgical procedure known as Sentinel Lymph Node Biopsy (SLNB). Neoprobe recently announced positive preliminary data from a Phase 2 multicenter clinical trial for Lymphoseek and is preparing to submit a proposed Phase 3 protocol to FDA.

Details of the non-binding term sheet will remain confidential until a definitive marketing and distribution arrangement has been negotiated and signed.

David Bupp, Neoprobe's President and CEO, said, "We are very pleased to have the opportunity to establish business terms for the marketing and distribution of Lymphoseek in the United States. The completion of this agreement, coupled with our recent announcement of preliminary results for the Phase 2 clinical evaluation of Lymphoseek, will be an important milestone event for the Company. We look forward to working with Cardinal Health to support the successful commercial launch of Lymphoseek in the United States."

Posts: 1045 | From: novato,ca,usa | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
metal1
Member


Rate Member
Icon 1 posted      Profile for metal1     Send New Private Message       Edit/Delete Post   Reply With Quote 
trading .46 today. earnings report on thurdaay. should be interesting
Posts: 1045 | From: novato,ca,usa | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
metal1
Member


Rate Member
Icon 1 posted      Profile for metal1     Send New Private Message       Edit/Delete Post   Reply With Quote 
back up to .40 again today. another earnings report due today. we'll see if this one is any good
Posts: 1045 | From: novato,ca,usa | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
metal1
Member


Rate Member
Icon 1 posted      Profile for metal1     Send New Private Message       Edit/Delete Post   Reply With Quote 
nice move last couple of days. trading .55 now. also received some new funding.

Neoprobe Receives Regulatory Clearance for Lymphoseek Clinical Study
8:35 AM EDT April 16, 2008
DUBLIN, Ohio--(BUSINESS WIRE)--

Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that Neoprobe has been informed by FDA of its agreement with the Company's plan to commence patient enrollment in a Phase 3 multi-center clinical study to evaluate the safety and efficacy of Lymphoseek(R), a lymphatic tissue targeting agent being developed by the Company. The agreement for the Company to commence enrollment follows FDA's review of Neoprobe's responses to information requested by FDA related to prior submissions by the Company regarding the chemistry, manufacturing and control and prior clinical testing of Lymphoseek. Neoprobe intends to enroll approximately two hundred (200) patients at up to twenty-five cancer treatment centers in the United States and Europe under the amended Phase 3 clinical protocol. Lymphoseek is intended to be used in biopsy procedures for the detection of lymph nodes in patients with breast cancer, melanoma and other tumor types.

David Bupp, Neoprobe's President, said, "To date, the clinical and preclinical results that have been completed demonstrate the benefits of Lymphoseek. We believe the safety and efficacy of Lymphoseek will be further supported by the completion of Phase 3 multi-center studies. In preparation for the initiation of the Phase 3 clinical studies, Neoprobe met with potential Phase 3 investigators at the Society of Surgical Oncology meeting in late March. We expect to begin patient enrollment in the first Phase 3 clinical study shortly after the FDA-approved clinical protocol and associated materials receive final clearance from review committees of the investigational sites."

The Company is also preparing for a second Phase 3 trial to involve less than 200 evaluable patients with head and neck squamous cell carcinoma. The second Phase 3 study is proposed to be conducted in patients undergoing full nodal dissection for the staging of head and neck squamous cell carcinoma and is intended to validate Lymphoseek as a lymph node targeting agent for use in Intraoperative Lymphatic Mapping procedures. The Company hopes to commence this second Phase 3 trial around mid-year.

Neoprobe also announced today in a separate news release that it has agreed to terms regarding $3 million of funding in the second tranche of investment in the Company by Platinum-Montaur Life Sciences LLC.

About Neoprobe

Posts: 1045 | From: novato,ca,usa | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
metal1
Member


Rate Member
Icon 1 posted      Profile for metal1     Send New Private Message       Edit/Delete Post   Reply With Quote 
holding at .60 now.
Posts: 1045 | From: novato,ca,usa | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
metal1
Member


Rate Member
Icon 1 posted      Profile for metal1     Send New Private Message       Edit/Delete Post   Reply With Quote 
another nice move today, closed at .77 up 17.4%. nothing on the wires though.
Posts: 1045 | From: novato,ca,usa | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
metal1
Member


Rate Member
Icon 1 posted      Profile for metal1     Send New Private Message       Edit/Delete Post   Reply With Quote 
closed at .81 today. nothing new on the wires. would like to see some news..
Posts: 1045 | From: novato,ca,usa | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
metal1
Member


Rate Member
Icon 1 posted      Profile for metal1     Send New Private Message       Edit/Delete Post   Reply With Quote 
been holding strong over $1. started as spec buy at Taglich Bros. Pay for coverage firm so i wouldn't put much into their report.
Posts: 1045 | From: novato,ca,usa | Registered: Aug 2003  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  New Poll  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share